Molecular map may guide treatment for mysterious inflammatory illnesses

NCT ID NCT03651518

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether analyzing a patient's DNA and RNA could help doctors pick the right drug for inflammatory diseases that don't fit standard categories. 32 adults with at least two affected organs (including skin) received one of six targeted therapies based on their molecular profile. The goal was to see if this personalized approach could improve symptoms and reduce inflammation at 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Kineret, Humira, Stelara, Cosentyx, Roactemra, Rituximab
What this could lead to: If successful, this approach could help doctors choose the right drug for patients with rare or hard-to-classify inflammatory diseases, improving treatment outcomes.
What could go wrong: This was a small, early-phase study (32 people) without a control group, so results may not apply broadly. The molecular analysis method may not reliably predict drug response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES INFLAMMATORY DISEASE

Contacts and locations

Locations

Hôpital Cochin

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.